Predictive biomarkers for MS
Stanford UniversityandPfizer Inc.researchers have reported that levels of IL-7 could help predictwhich multiple sclerosis patients will not respond to interferon-b therapy.1 Serum analysis of IL-7 together with a second marker identified last year by the Stanford team, IL-17F, which was only able to identify about 10% of nonresponders on its own, could predict up to one-third of nonresponders.
Stanford has spun out Atreca Inc. to develop predictive blood tests based on the findings.
Interferon-b (IFNB; IFN-b) is the standard first-line treatment for patients with relapsing-remitting multiple sclerosis (RRMS). Up to 25% of patients do not respond to the drugs, and treatment can even exacerbate the disease in some cases.
"The ability to identify patients who will versus